[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Siemens Medical Solutions USA, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":97},{"warningLetters":4,"total":96},[5,33,54,76],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},2483,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","Warning Letter","Closed Out","2022-08-30","631500","Medical Devices","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","VIA Electronic Mail","2022-08-03",{"id":34,"raw":35,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":47,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":20,"issuing_office":11,"recipient_name":51,"body_fetched_at":52,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":53,"medical_device_id":20,"response_letter_date":20},3595,[36,37,38,11,39,13,13,13],"\u003Ctime datetime=\"2026-08-18T04:00:00Z\">08\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-24T04:00:00Z\">07\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnipro-renal-solutions-usa-corporation-732874-07242026\"> Nipro Renal Solutions USA, Corporation \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n                          \u003Cbr>UDI\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tsuyoshi Yamazaki\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd> Nipro Renal Solutions USA, Corporation \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>509 Fishing Creek Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lewisberry\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>17339\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 732874\u003C\u002Fp>\u003Cp>July 16, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Yamazaki:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Lewisberry, PA from February 2, 2026 through March 27, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures dry and liquid hemodialysis dialysate concentrate solutions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality Management System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Rachael Nelsen, Vice President of Quality Affairs &amp; Regulatory Affairs, dated April 17, 2026 and May 29, 2026, and from Vikram Chandra, Senior Vice President of Quality Affairs &amp; Regulatory Affairs, dated July 14, 2026 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to ensure that product which does not conform to product requirements is identified and controlled to prevent its unintended use or delivery; and failure to document a procedure defining the controls and related responsibilities and authorities for the identification, documentation, segregation, evaluation, and disposition of nonconforming product, as required by ISO 13485:2016, Clause 8.3.1. Specifically,\u003C\u002Fp>\u003Cp>a. Your firm released and distributed finished hemodialysis products with out-of-specification (OOS) endotoxin results on multiple occasions. Specifically, your firm released the following lots of products despite your Laboratory Report Forms (DMR 5404) incorrectly indicated that endotoxin LAL testing had 'Passed,' and the Finished Product Packet (SOP QSM012; Effective Date 04\u002F28\u002F23) contained Quality's signed acceptance of each lot, despite each example exceeding the \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL endotoxin specification:\u003C\u002Fp>\u003Cul>\u003Cli>On May 6, 2025, MedicaLyte Bicarbonate Powder (45X), Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (expiration 04\u002F30\u002F2027), was released with an endotoxin result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL\u003C\u002Fli>\u003Cli>On December 18, 2025, MedicaLyte Bicarbonate Powder (DB+201-25), Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (expiration 12\u002F05\u002F2027), was released with an endotoxin result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL\u003C\u002Fli>\u003Cli>On May 22, 2025, Citric Complete Dry Citric Acid Concentrate, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (expiration 05\u002F19\u002F2027), was released with an endotoxin result of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL\u003C\u002Fli>\u003C\u002Ful>\u003Cp>b. Your firm's Investigations procedure (NRSU-SOP-0060, Revision 02, Effective Date December 8, 2025) and the Endotoxin Analysis work instruction (NRSU-WI-0061, Revision 02, Effective Date October 31, 2025, and Revision 01, Effective Date August 25, 2025) define processes for investigating OOS results. Section 7.2 of NRSU-SOP-0060 requires a MasterControl form for each investigation initiated for OOS results and issues found during production. However, an OOS log for January 2025 through February 2026, generated at investigators' request during the inspection, revealed thirteen product-related endotoxin failures and \u003Cstrong>(b)(4)\u003C\u002Fstrong> endotoxin failures for which your firm was unable to provide any documented investigation or nonconformance documentation.\u003C\u002Fp>\u003Cp>We reviewed your firm's responses and conclude that they are not adequate. Your firm provided Health Hazard Assessments (NRSU-RPT-0028 Rev 02 and NRSU-RPT-0045) asserting that retain samples of the above lots yielded compliant endotoxin results, and therefore no field action or customer notification is warranted, attributing the OOS documentation to documentation errors. However, retesting of retain samples is not an appropriate justification for not performing a field action or customer notification when the original test results demonstrated product with endotoxin test results exceeding specification. Furthermore, our Agency has reviewed these results and your firm’s response (including the Health Hazard Assessment and Customer Notification Determination) and has determined that these lots of products with endotoxin levels higher than specification may cause a risk to health, namely \u003Cstrong>(b)(4)\u003C\u002Fstrong> reactions. In your response, please provide what your firm’s planned action(s) are related to these adulterated, released lots of products.&nbsp;\u003C\u002Fp>\u003Cp>Additionally, your firm initiated CAPAs 26004 and 26005, with promised corrective actions including revisions to NRSU-SOP-0060 to establish clear, enforceable, and risk-based criteria for investigation initiation and escalation across all applicable quality events — including laboratory OOS results, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and utility monitoring failures, and nonconforming product. However, these items remain in progress as of your July 14, 2026 response. In response to this letter, provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>2. Failure to take action to eliminate the cause of nonconformities in order to prevent recurrence, failure to take any necessary corrective actions without undue delay, and failure to take corrective actions proportionate to the effects of the nonconformities encountered, as required by ISO 13485:2016, Clause 8.5.2.\u003C\u002Fp>\u003Cp>Specifically, your firm's Corrective and Preventive Action (CAPA) procedure (NRSU-SOP-0059, Revision 01, Effective Date 10\u002F08\u002F2024) has not been fully implemented in that corrective actions have not been proportionate to the effects of the nonconformities encountered, have not been taken without undue delay, and have not prevented recurrence of nonconformities. For example:\u003C\u002Fp>\u003Cul>\u003Cli>CAPA-25012 (initiated June 13, 2025, for endotoxin documentation failures) was found to be ineffective when your firm discovered that Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, MedicaLyte Bicarbonate Powder (DB+201-25), was released with an OOS endotoxin result after corrective actions had been implemented, demonstrating recurrence of the nonconformance.\u003C\u002Fli>\u003Cli>CAPA-25014 (initiated August 4, 2025 to address facility and equipment maintenance deficiencies including corrosion, contamination, and poor environmental controls in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room) was extended on January 19, 2026, to a revised due date of March 30, 2026. Despite this, during a facility tour on February 13, 2026 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> days after CAPA initiation), product residue was observed to be accumulated on and suspended from bottle filling machine nozzles, demonstrating that necessary corrective actions had not been taken without undue delay.\u003C\u002Fli>\u003Cli>CAPA-25005 (initiated May 22, 2025, for failing to follow the Monitoring Production Systems procedure) had a corrective action expected completion date of April 9, 2026 which is approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> days from initiation. Despite this, review of quality packets from September 2025, November 2025, and January 2026 during the inspection found that maintenance, sanitization, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring forms continued to be missing and\u002For incomplete, demonstrating that necessary corrective actions had not been taken without undue delay.\u003C\u002Fli>\u003Cli>CAPA-25010 (initiated June 4, 2025, for failure to follow and perform sampling of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system per NRSU-SOP-0039) corrective actions were completed on January 6, 2026. However, inspection review of January 2026 \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring records revealed that multiple sample port tests and \u003Cstrong>(b)(4)\u003C\u002Fstrong> had not been conducted for colony count and endotoxin monitoring without any documented justification, demonstrating that your firm failed to eliminate the cause of nonconformities to prevent recurrence.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm stated that CAPAs 25005, 25010, 25014, and 25015 had all been initiated prior to the current FDA inspection. Your firm's response promises revisions to NRSU-SOP-0059, implementation of a CAPA tracking system, and training for applicable personnel, with a target completion date of August 7, 2026. CAPA-25015, which directly addresses your CAPA process itself, remains open. None of the underlying nonconformances addressed by the above CAPAs have been resolved, and all remain ongoing or have reoccurred. In response to this letter provide documentation for any status updates for the outstanding corrective actions, including verification of effectiveness, when completed. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>3. Failure to document procedures for design and development, as required by ISO 13485:2016, Clause 7.3.1.\u003C\u002Fp>\u003Cp>Specifically, although your firm maintains procedure NRSU-SOP-0018, Design Control (Revision 00, Effective Date 05\u002F01\u002F2020), and your Quality Manual (NRSU-MAN-0001, Revision 01, Effective Date 04\u002F21\u002F2025) describe design and development requirements including design and development planning, design input, design output, design review, design verification and validation, design transfer, design changes, and design history file your firm was unable to produce any records during the inspection demonstrating that any of your six marketed devices were developed in accordance with Clause 7.3, No design and development files have been maintained for your six products cleared under K223431, K193155, K171750, K012547, K131202, or K901471.\u003C\u002Fp>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25026 which commits to performing a DHF Gap Assessment and Reconstruction Program, with a gap assessment completion targeted for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and remediation timelines to be established thereafter. However, these items remain in progress as of your July 14, 2026 response. In response to this letter provide documentation for any outstanding corrective actions, including CAPA verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>4. Failure to document procedures to control design and development changes, as required by ISO 13485:2016, Clause 7.3.9.\u003C\u002Fp>\u003Cp>Specifically, your firm's design control procedure, NRSU-SOP-0018 (Revision 00, Effective Date 05\u002F01\u002F2020), does not include a design change process, and instead references your change control procedure NRSU-SOP-0019. However, NRSU-SOP-0019 does not include a requirement for evaluation of the effect of the changes on constituent parts and product in process or already delivered, including inputs and outputs of risk management and product realization processes, such as design and development verification and validation activities. The following design changes were implemented without the required design and development change records, risk analyses, or documented impact assessments:\u003C\u002Fp>\u003Cul>\u003Cli>Transition from \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging for the dry product lines in September 2023\u003C\u002Fli>\u003Cli>Change in the thickness of the primary packaging film from \u003Cstrong>(b)(4)\u003C\u002Fstrong> for both dry product lines in September 2023\u003C\u002Fli>\u003Cli>Change of the endotoxin level specification from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL to \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL for the Liquid Citric Acid Concentrate LC 228 (45x) in March 2025\u003C\u002Fli>\u003Cli>Change of the endotoxin level specification from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL to \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Liquid Acidic Concentrate products in March 2025\u003C\u002Fli>\u003Cli>Change of the endotoxin level specification from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL to \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL for the Liquid Acidic Concentrate AC 213 (45x) in April 2025\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25026, which promises retrospective design change impact assessments, initiation of change records, revision to NRSU-SOP-0018 (targeted completion July 31, 2026), and revision to NRSU-SOP-0019 (targeted completion October 31, 2026). In response to this letter provide documentation for any outstanding corrective actions, including CAPA verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>5. Failure to document the requirements for infrastructure needed to achieve conformity to product requirements, prevent product mix-up, and ensure orderly handling of product, as required by ISO 13485:2016, Clause 6.3.\u003C\u002Fp>\u003Cp>Specifically, your firm has failed to perform maintenance on buildings, workspaces, associated utilities as well as process equipment as required by Clause 6.3(a) and (b). Your procedures NRSU-SOP-0037 'Monitoring Production Systems' (Revision 00, Effective Date 04\u002F13\u002F2020) and NRSU-WI-0040 'Operation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> System' (Revision 00, Effective Date 03\u002F30\u002F2020) govern operation and maintenance of production systems, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system and bottle filling equipment. During a facility walkthrough on February 13, 2026, our investigator observed multiple pipes leaking in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Your firm was unable to provide any documentation related to these leaks, including repairs made, corrective actions taken, or an assessment of the impact of these leaks and repairs on \u003Cstrong>(b)(4)\u003C\u002Fstrong> functionality and continued conformity to requirements.\u003C\u002Fp>\u003Cp>Additionally, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is the only instrument used for endotoxin testing including \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring and final product acceptance. Your firm was unable to provide records demonstrating that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been changed or that preventive maintenance had ever been performed for this instrument, despite Section 7 of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Operator Manual (Revision A, 2025) requiring \u003Cstrong>(b)(4)\u003C\u002Fstrong> replacement and recommended \u003Cstrong>(b)(4)\u003C\u002Fstrong> service intervals.\u003C\u002Fp>\u003Cp>We reviewed your firm's responses and conclude that they are not adequate. Your firm initiated CAPA-25027, which promises implementation of a validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> through multiple phases with a target completion date of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and an assessment to identify infrastructure with overdue or incomplete maintenance, calibration, or validation activities by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your firm's responses do not specifically address any corrections or corrective actions planned for the numerous pipe leaks observed, including repairs planned or made or an assessment of the impact on product quality. In addition, provide any documentation for the outstanding corrective actions, including verification of effectiveness. If corrective actions will not be complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>6. Failure to perform calibration or verification of measuring equipment in accordance with documented procedures, as required by ISO 13485:2016, Clause 7.6.\u003C\u002Fp>\u003Cp>Specifically, your firm's calibration work instruction NRSU-WI-0012 'Calibrations' (Revision 00, Effective Date 04\u002F10\u002F2020) has not been implemented. For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> (serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>) is the sole instrument used for endotoxin testing for both \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring and final product release across all product lines. Despite being in use since December 18, 2023, this instrument has never been calibrated, and a calibration schedule has never been established. Furthermore, your firm's work instruction NRSU-WI-0061 (Revision 03, Effective Date 12\u002F03\u002F2025) required \u003Cstrong>(b)(4)\u003C\u002Fstrong> calibration reports; however, no reports were provided.\u003C\u002Fp>\u003Cp>We reviewed your firm's responses and conclude that they are not adequate. While we acknowledge your firm initiated CAPA-25027, which promises implementation of a validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> with planned completion by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and an infrastructure\u002Fmaintenance assessment by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm has not provided a plan to assess the validity of previous test results obtained using the uncalibrated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, nor any proposed action for product previously released based on those results. In response to this letter provide any planned evaluation and assessment related to results obtained from this uncalibrated instrument as well as documentation for any other outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>7. Failure to document procedures for validation of processes for production and service provisions, as required by ISO 13485:2016, Clause 7.5.6.\u003C\u002Fp>\u003Cp>Specifically, your firm does not have a documented procedure for validation of processes for production equipment. Your work instruction NRSU-WI-0029 'Validated Systems and Equipment Change' (Revision 00, Effective Date 07\u002F12\u002F2021), was provided as the sole document governing validation. This work instruction does not include all the requirements found within sections a) through g) of Clause 7.5.6.\u003C\u002Fp>\u003Cp>Additionally, your firm was unable to provide documentation that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> (serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>), which is used for endotoxin monitoring of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and final product release was validated as the only document provided was a combined Installation, Operational, and Performance Qualification (IOPQ) test results from December 15 and 18, 2023. This document only provides testing results for products with an endotoxin specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002FmL. The following endotoxin testing applications performed routinely by your firm were not included in this IOPQ document and have not been adequately validated:\u003C\u002Fp>\u003Cul>\u003Cli>Endotoxin testing of all liquid product lines (Liquid Acidic Concentrate, Liquid Citric Acid Concentrate, and Liquid Sodium Bicarbonate Hemodialysis Solution)\u003C\u002Fli>\u003Cli>The retesting procedure for endotoxin results found to be out-of-specification.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your firm initiated CAPA-25002 prior to the current inspection and completed additional performance qualification (PQ) activities for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> instrument, which were provided in your July 14, 2026 response. However, this additional PQ (NRSU-VAL-0153 Addendum 1) was limited to your Liquid Acetic Acid products. In response to this letter provide any PQ activities for your other product lines as well as documentation for any other outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>8. Failure to document one or more processes for risk management in product realization, as required by ISO 13485:2016, Clause 7.1.\u003C\u002Fp>\u003Cp>Specifically, your firm has not established a systematic, documented, risk-based approach to identifying, evaluating, and controlling risks associated with product realization processes. For example, your firm does not have policies, procedures, or practices for overall risk management, design risk analysis, or process risk analysis with requirements for continual evaluation and updates. Your firm maintains risk analysis reports for each of its products; however, these reports have not been updated since their initial creation. For example, the risk analysis for MedicaLyte Liquid Bicarbonate (NRSU-RPT-0004, Effective Date 11\u002F13\u002F2020) states that all risks are either negligible or acceptable. Despite an ongoing Class I Recall (Z-1730-2025 \u002F RES 96646) of MedicaLyte Liquid Bicarbonate Concentrate initiated April 11, 2025, due to microbial and fungal contamination, the risk analysis for this product has not been updated since November 13, 2020. Your firm's design control procedure NRSU-SOP-0018 (Revision 00, Effective Date 05\u002F01\u002F2020) requires updates to risk management documentation when known and potential hazards are identified.\u003C\u002Fp>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25006 prior to the current inspection with plans to develop a risk management SOP, review and revise existing product and process risk analysis reports once the new SOP is implemented, and train affected staff, with a target completion date of October 31, 2026. In response to this letter provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>9. Failure to monitor supplier performance in meeting requirements for purchased product, as required by ISO 13485:2016, Clause 7.4.1.\u003C\u002Fp>\u003Cp>Specifically, your firm's supplier management procedure (NRSU-SOP-0022, Revision 04, Effective Date December 2, 2025) documents your process for classification and evaluation of suppliers. However, your firm was unable to provide any records demonstrating that suppliers and services had ever been classified or evaluated in accordance with this procedure.\u003C\u002Fp>\u003Cp>The adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25024 prior to the current FDA inspection and has taken immediate corrections by reviewing and updating the approved supplier list (ASL) and increasing supplier oversight until evaluations and\u002For audits are completed. Corrective actions planned include revision of the supplier management SOP, strengthening supplier audit controls, improvements to the SCAR process, and implementation of quality agreements for all Level I (\u003Cstrong>(b)(4)\u003C\u002Fstrong> risk) suppliers, with a target completion date of November 20, 2026. However, several of these items remain in progress as of your July 14, 2026 response. In response to this letter provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identification Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bears a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Nipro Dry complete dry acid concentrate for hemodialysis devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>In addition, the Nipro Dry complete dry acid concentrate for hemodialysis is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B). Based on review of the Global Unique Device Identification Database (GUDID) on June 11, 2026, there are no entries for Nipro Dry complete dry acid concentrate for hemodialysis.\u003C\u002Fp>\u003Cp>A follow up inspection will be required to ensure that corrections and\u002For corrective actions are adequate.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 732874” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at sean.moynihan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CAPT Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>Cc: Vikram Chandra, Sr. VP QA\u002FRA - Nipro Americas Group Companies, Inc., Vikram.Chandra@nipromed.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nUDI\n\nRecipient:\n\nRecipient Name\n\nTsuyoshi Yamazaki\n\nRecipient Title\n\nPresident\n\nNipro Renal Solutions USA, Corporation\n\n509 Fishing Creek Road\n\nLewisberry, PA 17339\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nCMS # 732874\nJuly 16, 2026\nDear Mr. Yamazaki:\nDuring an inspection of your firm located in Lewisberry, PA from February 2, 2026 through March 27, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures dry and liquid hemodialysis dialysate concentrate solutions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality Management System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Rachael Nelsen, Vice President of Quality Affairs & Regulatory Affairs, dated April 17, 2026 and May 29, 2026, and from Vikram Chandra, Senior Vice President of Quality Affairs & Regulatory Affairs, dated July 14, 2026 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to ensure that product which does not conform to product requirements is identified and controlled to prevent its unintended use or delivery; and failure to document a procedure defining the controls and related responsibilities and authorities for the identification, documentation, segregation, evaluation, and disposition of nonconforming product, as required by ISO 13485:2016, Clause 8.3.1. Specifically,\na. Your firm released and distributed finished hemodialysis products with out-of-specification (OOS) endotoxin results on multiple occasions. Specifically, your firm released the following lots of products despite your Laboratory Report Forms (DMR 5404) incorrectly indicated that endotoxin LAL testing had 'Passed,' and the Finished Product Packet (SOP QSM012; Effective Date 04\u002F28\u002F23) contained Quality's signed acceptance of each lot, despite each example exceeding the (b)(4)\u002FmL endotoxin specification:\nOn May 6, 2025, MedicaLyte Bicarbonate Powder (45X), Lot (b)(4) (expiration 04\u002F30\u002F2027), was released with an endotoxin result of (b)(4)\u002FmL\nOn December 18, 2025, MedicaLyte Bicarbonate Powder (DB+201-25), Lot (b)(4) (expiration 12\u002F05\u002F2027), was released with an endotoxin result of (b)(4)\u002FmL\nOn May 22, 2025, Citric Complete Dry Citric Acid Concentrate, Lot (b)(4) (expiration 05\u002F19\u002F2027), was released with an endotoxin result of (b)(4)\u002FmL\nb. Your firm's Investigations procedure (NRSU-SOP-0060, Revision 02, Effective Date December 8, 2025) and the Endotoxin Analysis work instruction (NRSU-WI-0061, Revision 02, Effective Date October 31, 2025, and Revision 01, Effective Date August 25, 2025) define processes for investigating OOS results. Section 7.2 of NRSU-SOP-0060 requires a MasterControl form for each investigation initiated for OOS results and issues found during production. However, an OOS log for January 2025 through February 2026, generated at investigators' request during the inspection, revealed thirteen product-related endotoxin failures and (b)(4) endotoxin failures for which your firm was unable to provide any documented investigation or nonconformance documentation.\nWe reviewed your firm's responses and conclude that they are not adequate. Your firm provided Health Hazard Assessments (NRSU-RPT-0028 Rev 02 and NRSU-RPT-0045) asserting that retain samples of the above lots yielded compliant endotoxin results, and therefore no field action or customer notification is warranted, attributing the OOS documentation to documentation errors. However, retesting of retain samples is not an appropriate justification for not performing a field action or customer notification when the original test results demonstrated product with endotoxin test results exceeding specification. Furthermore, our Agency has reviewed these results and your firm’s response (including the Health Hazard Assessment and Customer Notification Determination) and has determined that these lots of products with endotoxin levels higher than specification may cause a risk to health, namely (b)(4) reactions. In your response, please provide what your firm’s planned action(s) are related to these adulterated, released lots of products.\nAdditionally, your firm initiated CAPAs 26004 and 26005, with promised corrective actions including revisions to NRSU-SOP-0060 to establish clear, enforceable, and risk-based criteria for investigation initiation and escalation across all applicable quality events — including laboratory OOS results, (b)(4) and utility monitoring failures, and nonconforming product. However, these items remain in progress as of your July 14, 2026 response. In response to this letter, provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n2. Failure to take action to eliminate the cause of nonconformities in order to prevent recurrence, failure to take any necessary corrective actions without undue delay, and failure to take corrective actions proportionate to the effects of the nonconformities encountered, as required by ISO 13485:2016, Clause 8.5.2.\nSpecifically, your firm's Corrective and Preventive Action (CAPA) procedure (NRSU-SOP-0059, Revision 01, Effective Date 10\u002F08\u002F2024) has not been fully implemented in that corrective actions have not been proportionate to the effects of the nonconformities encountered, have not been taken without undue delay, and have not prevented recurrence of nonconformities. For example:\nCAPA-25012 (initiated June 13, 2025, for endotoxin documentation failures) was found to be ineffective when your firm discovered that Lot (b)(4), MedicaLyte Bicarbonate Powder (DB+201-25), was released with an OOS endotoxin result after corrective actions had been implemented, demonstrating recurrence of the nonconformance.\nCAPA-25014 (initiated August 4, 2025 to address facility and equipment maintenance deficiencies including corrosion, contamination, and poor environmental controls in the (b)(4) room) was extended on January 19, 2026, to a revised due date of March 30, 2026. Despite this, during a facility tour on February 13, 2026 ((b)(4) days after CAPA initiation), product residue was observed to be accumulated on and suspended from bottle filling machine nozzles, demonstrating that necessary corrective actions had not been taken without undue delay.\nCAPA-25005 (initiated May 22, 2025, for failing to follow the Monitoring Production Systems procedure) had a corrective action expected completion date of April 9, 2026 which is approximately (b)(4) days from initiation. Despite this, review of quality packets from September 2025, November 2025, and January 2026 during the inspection found that maintenance, sanitization, and (b)(4) monitoring forms continued to be missing and\u002For incomplete, demonstrating that necessary corrective actions had not been taken without undue delay.\nCAPA-25010 (initiated June 4, 2025, for failure to follow and perform sampling of the (b)(4) system per NRSU-SOP-0039) corrective actions were completed on January 6, 2026. However, inspection review of January 2026 (b)(4) monitoring records revealed that multiple sample port tests and (b)(4) had not been conducted for colony count and endotoxin monitoring without any documented justification, demonstrating that your firm failed to eliminate the cause of nonconformities to prevent recurrence.\nThe adequacy of your firm's responses cannot be determined at this time. Your firm stated that CAPAs 25005, 25010, 25014, and 25015 had all been initiated prior to the current FDA inspection. Your firm's response promises revisions to NRSU-SOP-0059, implementation of a CAPA tracking system, and training for applicable personnel, with a target completion date of August 7, 2026. CAPA-25015, which directly addresses your CAPA process itself, remains open. None of the underlying nonconformances addressed by the above CAPAs have been resolved, and all remain ongoing or have reoccurred. In response to this letter provide documentation for any status updates for the outstanding corrective actions, including verification of effectiveness, when completed. If corrective actions are not complete, provide a timeframe for completion.\n3. Failure to document procedures for design and development, as required by ISO 13485:2016, Clause 7.3.1.\nSpecifically, although your firm maintains procedure NRSU-SOP-0018, Design Control (Revision 00, Effective Date 05\u002F01\u002F2020), and your Quality Manual (NRSU-MAN-0001, Revision 01, Effective Date 04\u002F21\u002F2025) describe design and development requirements including design and development planning, design input, design output, design review, design verification and validation, design transfer, design changes, and design history file your firm was unable to produce any records during the inspection demonstrating that any of your six marketed devices were developed in accordance with Clause 7.3, No design and development files have been maintained for your six products cleared under K223431, K193155, K171750, K012547, K131202, or K901471.\nThe adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25026 which commits to performing a DHF Gap Assessment and Reconstruction Program, with a gap assessment completion targeted for (b)(4), and remediation timelines to be established thereafter. However, these items remain in progress as of your July 14, 2026 response. In response to this letter provide documentation for any outstanding corrective actions, including CAPA verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n4. Failure to document procedures to control design and development changes, as required by ISO 13485:2016, Clause 7.3.9.\nSpecifically, your firm's design control procedure, NRSU-SOP-0018 (Revision 00, Effective Date 05\u002F01\u002F2020), does not include a design change process, and instead references your change control procedure NRSU-SOP-0019. However, NRSU-SOP-0019 does not include a requirement for evaluation of the effect of the changes on constituent parts and product in process or already delivered, including inputs and outputs of risk management and product realization processes, such as design and development verification and validation activities. The following design changes were implemented without the required design and development change records, risk analyses, or documented impact assessments:\nTransition from (b)(4) packaging for the dry product lines in September 2023\nChange in the thickness of the primary packaging film from (b)(4) for both dry product lines in September 2023\nChange of the endotoxin level specification from (b)(4)\u002FmL to (b)(4)\u002FmL for the Liquid Citric Acid Concentrate LC 228 (45x) in March 2025\nChange of the endotoxin level specification from (b)(4)\u002FmL to (b)(4)\u002FmL for (b)(4) Liquid Acidic Concentrate products in March 2025\nChange of the endotoxin level specification from (b)(4)\u002FmL to (b)(4)\u002FmL for the Liquid Acidic Concentrate AC 213 (45x) in April 2025\nThe adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25026, which promises retrospective design change impact assessments, initiation of change records, revision to NRSU-SOP-0018 (targeted completion July 31, 2026), and revision to NRSU-SOP-0019 (targeted completion October 31, 2026). In response to this letter provide documentation for any outstanding corrective actions, including CAPA verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n5. Failure to document the requirements for infrastructure needed to achieve conformity to product requirements, prevent product mix-up, and ensure orderly handling of product, as required by ISO 13485:2016, Clause 6.3.\nSpecifically, your firm has failed to perform maintenance on buildings, workspaces, associated utilities as well as process equipment as required by Clause 6.3(a) and (b). Your procedures NRSU-SOP-0037 'Monitoring Production Systems' (Revision 00, Effective Date 04\u002F13\u002F2020) and NRSU-WI-0040 'Operation of the (b)(4) System' (Revision 00, Effective Date 03\u002F30\u002F2020) govern operation and maintenance of production systems, including the (b)(4) system and bottle filling equipment. During a facility walkthrough on February 13, 2026, our investigator observed multiple pipes leaking in the (b)(4) system. Your firm was unable to provide any documentation related to these leaks, including repairs made, corrective actions taken, or an assessment of the impact of these leaks and repairs on (b)(4) functionality and continued conformity to requirements.\nAdditionally, the (b)(4) (serial number (b)(4)) is the only instrument used for endotoxin testing including (b)(4) monitoring and final product acceptance. Your firm was unable to provide records demonstrating that the (b)(4) had been changed or that preventive maintenance had ever been performed for this instrument, despite Section 7 of the (b)(4) Operator Manual (Revision A, 2025) requiring (b)(4) replacement and recommended (b)(4) service intervals.\nWe reviewed your firm's responses and conclude that they are not adequate. Your firm initiated CAPA-25027, which promises implementation of a validated (b)(4) through multiple phases with a target completion date of (b)(4), and an assessment to identify infrastructure with overdue or incomplete maintenance, calibration, or validation activities by (b)(4). However, your firm's responses do not specifically address any corrections or corrective actions planned for the numerous pipe leaks observed, including repairs planned or made or an assessment of the impact on product quality. In addition, provide any documentation for the outstanding corrective actions, including verification of effectiveness. If corrective actions will not be complete, provide a timeframe for completion.\n6. Failure to perform calibration or verification of measuring equipment in accordance with documented procedures, as required by ISO 13485:2016, Clause 7.6.\nSpecifically, your firm's calibration work instruction NRSU-WI-0012 'Calibrations' (Revision 00, Effective Date 04\u002F10\u002F2020) has not been implemented. For example, the (b)(4) (serial number (b)(4)) is the sole instrument used for endotoxin testing for both (b)(4) monitoring and final product release across all product lines. Despite being in use since December 18, 2023, this instrument has never been calibrated, and a calibration schedule has never been established. Furthermore, your firm's work instruction NRSU-WI-0061 (Revision 03, Effective Date 12\u002F03\u002F2025) required (b)(4) calibration reports; however, no reports were provided.\nWe reviewed your firm's responses and conclude that they are not adequate. While we acknowledge your firm initiated CAPA-25027, which promises implementation of a validated (b)(4) with planned completion by (b)(4), and an infrastructure\u002Fmaintenance assessment by (b)(4). Your firm has not provided a plan to assess the validity of previous test results obtained using the uncalibrated (b)(4), nor any proposed action for product previously released based on those results. In response to this letter provide any planned evaluation and assessment related to results obtained from this uncalibrated instrument as well as documentation for any other outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n7. Failure to document procedures for validation of processes for production and service provisions, as required by ISO 13485:2016, Clause 7.5.6.\nSpecifically, your firm does not have a documented procedure for validation of processes for production equipment. Your work instruction NRSU-WI-0029 'Validated Systems and Equipment Change' (Revision 00, Effective Date 07\u002F12\u002F2021), was provided as the sole document governing validation. This work instruction does not include all the requirements found within sections a) through g) of Clause 7.5.6.\nAdditionally, your firm was unable to provide documentation that your (b)(4) (serial number (b)(4)), which is used for endotoxin monitoring of (b)(4) and final product release was validated as the only document provided was a combined Installation, Operational, and Performance Qualification (IOPQ) test results from December 15 and 18, 2023. This document only provides testing results for products with an endotoxin specification of (b)(4)\u002FmL. The following endotoxin testing applications performed routinely by your firm were not included in this IOPQ document and have not been adequately validated:\nEndotoxin testing of all liquid product lines (Liquid Acidic Concentrate, Liquid Citric Acid Concentrate, and Liquid Sodium Bicarbonate Hemodialysis Solution)\nThe retesting procedure for endotoxin results found to be out-of-specification.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your firm initiated CAPA-25002 prior to the current inspection and completed additional performance qualification (PQ) activities for the (b)(4) instrument, which were provided in your July 14, 2026 response. However, this additional PQ (NRSU-VAL-0153 Addendum 1) was limited to your Liquid Acetic Acid products. In response to this letter provide any PQ activities for your other product lines as well as documentation for any other outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n8. Failure to document one or more processes for risk management in product realization, as required by ISO 13485:2016, Clause 7.1.\nSpecifically, your firm has not established a systematic, documented, risk-based approach to identifying, evaluating, and controlling risks associated with product realization processes. For example, your firm does not have policies, procedures, or practices for overall risk management, design risk analysis, or process risk analysis with requirements for continual evaluation and updates. Your firm maintains risk analysis reports for each of its products; however, these reports have not been updated since their initial creation. For example, the risk analysis for MedicaLyte Liquid Bicarbonate (NRSU-RPT-0004, Effective Date 11\u002F13\u002F2020) states that all risks are either negligible or acceptable. Despite an ongoing Class I Recall (Z-1730-2025 \u002F RES 96646) of MedicaLyte Liquid Bicarbonate Concentrate initiated April 11, 2025, due to microbial and fungal contamination, the risk analysis for this product has not been updated since November 13, 2020. Your firm's design control procedure NRSU-SOP-0018 (Revision 00, Effective Date 05\u002F01\u002F2020) requires updates to risk management documentation when known and potential hazards are identified.\nThe adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25006 prior to the current inspection with plans to develop a risk management SOP, review and revise existing product and process risk analysis reports once the new SOP is implemented, and train affected staff, with a target completion date of October 31, 2026. In response to this letter provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\n9. Failure to monitor supplier performance in meeting requirements for purchased product, as required by ISO 13485:2016, Clause 7.4.1.\nSpecifically, your firm's supplier management procedure (NRSU-SOP-0022, Revision 04, Effective Date December 2, 2025) documents your process for classification and evaluation of suppliers. However, your firm was unable to provide any records demonstrating that suppliers and services had ever been classified or evaluated in accordance with this procedure.\nThe adequacy of your firm's responses cannot be determined at this time. Your firm initiated CAPA-25024 prior to the current FDA inspection and has taken immediate corrections by reviewing and updating the approved supplier list (ASL) and increasing supplier oversight until evaluations and\u002For audits are completed. Corrective actions planned include revision of the supplier management SOP, strengthening supplier audit controls, improvements to the SCAR process, and implementation of quality agreements for all Level I ((b)(4) risk) suppliers, with a target completion date of November 20, 2026. However, several of these items remain in progress as of your July 14, 2026 response. In response to this letter provide documentation for any outstanding corrective actions, including verification of effectiveness. If corrective actions are not complete, provide a timeframe for completion.\nUnique Device Identification Violations\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a), which was promulgated under authority of section 519 of the Act, among other provisions, requires, with exceptions not relevant here, that the label of every medical device bears a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Nipro Dry complete dry acid concentrate for hemodialysis devices do not bear such a UDI. For example, the labels for these devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, there is no UDI presented in easily readable plain-text (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology (see 21 CFR 801.40(a)(2)).\nIn addition, the Nipro Dry complete dry acid concentrate for hemodialysis is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the devices. In particular, 21 CFR 830.300(a) and 830.320(b), both of which were promulgated under section 519 of the Act, among other provisions, require, with exceptions not relevant here, that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. Your firm is a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B). Based on review of the Global Unique Device Identification Database (GUDID) on June 11, 2026, there are no entries for Nipro Dry complete dry acid concentrate for hemodialysis.\nA follow up inspection will be required to ensure that corrections and\u002For corrective actions are adequate.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 1 Assistant Director Gina Brackett at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 732874” when replying. If you have any questions about the contents of this letter, please contact: Sean Moynihan at sean.moynihan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCAPT Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCc: Vikram Chandra, Sr. VP QA\u002FRA - Nipro Americas Group Companies, Inc., Vikram.Chandra@nipromed.com","Nipro Renal Solutions USA, Corporation","nipro-renal-solutions-usa-corporation-732874-07242026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnipro-renal-solutions-usa-corporation-732874-07242026","2026-10-26T08:09:34.119232+00:00","Issued","2026-08-18","732874","Medical Devices UDI","Tsuyoshi Yamazaki","2026-08-19T04:26:47.114+00:00","2026-07-24",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":20,"letter_url":67,"updated_at":68,"action_type":23,"case_status":47,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":20,"issuing_office":60,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":20,"reference_number":20,"action_taken_date":75,"medical_device_id":20,"response_letter_date":20},3123,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-29T04:00:00Z\">09\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-chemical-solutions-llc-616672-09292021\">True Chemical Solutions, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Permit Access to or Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Travis Pitcock\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>True Chemical Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6215 W. County Road 112\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Midland\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>79706\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-21-60\u003C\u002Fp>\n\n\u003Cp>September 29, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Pitcock:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products listed include HAPPY HANDS Hand Sanitizer Topical Gel with Moisturizing Solution. On November 10, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered, as did numerous telephone calls from the Agency regarding this matter, so the Agency sent a follow-up written request for such records and other information by certified return-receipt mail on May 4, 2021. Delivery was confirmed by your signature, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\u003C\u002Fp>\n\n\u003Cp>Since declaration of the COVID-19 public health emergency,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> a number of hand sanitizer products have been recalled due to quality issues ranging from substitution with other drug substances to subpotency.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>We note that, while your firm is registered with the FDA as a manufacturer of OTC drug products, your website indicates your firm is also involved in pipeline operations and fracturing, also known as fracking. Fracking operations typically involve multiple chemicals that could be harmful to patients if they were to contaminate drugs, such as your hand sanitizers.\u003C\u002Fp>\n\n\u003Cp>Respond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\u003C\u002Fp>\n\n\u003Cp>The Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>Continued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>You may provide additional information for our consideration as we continue to assess your activities and practices.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016866715 and ATTN: Marisa Heayn.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The HHS Declaration of a Public Health Emergency is available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Travis Pitcock\n\nRecipient Title\n\nChief Executive Officer\n\nTrue Chemical Solutions, LLC\n\n6215 W. County Road 112\n\nMidland, TX 79706\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-60\n\nSeptember 29, 2021\n\nDear Mr. Pitcock:\n\nYour firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products listed include HAPPY HANDS Hand Sanitizer Topical Gel with Moisturizing Solution. On November 10, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered, as did numerous telephone calls from the Agency regarding this matter, so the Agency sent a follow-up written request for such records and other information by certified return-receipt mail on May 4, 2021. Delivery was confirmed by your signature, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\n\nSince declaration of the COVID-19 public health emergency,1 a number of hand sanitizer products have been recalled due to quality issues ranging from substitution with other drug substances to subpotency.2 The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nWe note that, while your firm is registered with the FDA as a manufacturer of OTC drug products, your website indicates your firm is also involved in pipeline operations and fracturing, also known as fracking. Fracking operations typically involve multiple chemicals that could be harmful to patients if they were to contaminate drugs, such as your hand sanitizers.\n\nRespond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\n\nThe Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\n\nContinued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nYou may provide additional information for our consideration as we continue to assess your activities and practices.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nIdentify your response with FEI 3016866715 and ATTN: Marisa Heayn.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\n__________________________\n\n1 The HHS Declaration of a Public Health Emergency is available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx.\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance.","True Chemical Solutions, LLC","true-chemical-solutions-llc-616672-09292021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-chemical-solutions-llc-616672-09292021","2026-10-26T08:10:15.483298+00:00","2021-10-05","616672","Drugs","Mr. Travis Pitcock","2026-08-20T02:35:09.615+00:00","VIA UPS","2021-09-29",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":19,"fei_number":20,"letter_url":88,"updated_at":89,"action_type":23,"case_status":47,"posted_date":90,"marcs_cms_no":91,"product_type":92,"closeout_date":20,"issuing_office":82,"recipient_name":93,"body_fetched_at":94,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":95,"medical_device_id":20,"response_letter_date":20},2148,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2023-03-28T13:20:00Z\">03\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-07T05:00:00Z\">11\u002F07\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftodos-medical-ltd-aka-todos-medical-usa-inc-626258-11072022\">Todos Medical Ltd aka Todos Medical USA Inc\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gerald Commissiong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u002FDirector\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Todos Medical Ltd aka Todos Medical USA Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>40 Wall Street Suite 2702\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10005\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:gerald@todosmedical.com\"> gerald@todosmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: November 7, 2022\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fwww.todosmedical.com, https:\u002F\u002Fwww.mytollovid.com and https:\u002F\u002Fwww.tollovid.myshopify.com on June 23, 2022. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Ftodosmedical and https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCWsJLl1iB9qlZUSicQ9e-Mg, where you direct consumers to your websites https:\u002F\u002Fwww.mytollovid.com and https:\u002F\u002Fwww.todosmedical.com, respectively, to purchase your products. Additionally, we reviewed your product listings on your Amazon storefront at https:\u002F\u002Fwww.amazon.com\u002Fs?ie=UTF8&amp;marketplaceID=ATVPDKIKX0DER&amp;me=A1DTBIYVC3OVND. The FDA has observed that your websites and your Amazon storefront offer the product Tollovid 3CL Protease Inhibitor Delayed Release (Tollovid) for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your websites that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cp>• “3CL Protease Inhibitors: The Potential Key to Combating the SARS-CoV-2 Virus Life Cycle . . . Studies have shown … that by using protease inhibitors, we can stop the virus’ ability to replicate itself, halting the spread in it [sic] tracks.” [from your website https:\u002F\u002Ftodosmedical.com\u002F3cl- protease-inhibitors?hsLang=en]\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Protease Inhibitors”:\u003Cbr>\n“Todos has acquired exclusive distribution rights to the immune boosting, dietary supplement Tollovid™ and is developing Tollovir,™ a highly potent 3CL protease inhibitor as a COVID-10 antiviral.” [from your homepage at https:\u002F\u002Fwww.todosmedical.com]\u003C\u002Fp>\n\n\u003Cp>• \"What is a 3CL Protease?\u003Cbr>\nFormally known as C3 Endopeptidase, the main protease found in coronaviruses.\" [from https:\u002F\u002Fmytollovid.com\u002Fa\u002Ffaq]\u003C\u002Fp>\n\n\u003Cp>• \"Todos Medical featured in a new Seeking Alpha article: Pfizer's #3CL #Protease #Inhibitor May Cut the Achilles’ Heel of #COVID19\u003Cbr>\n. . .\u003Cbr>\nTodos . . .has a promising pipeline of products . . . Its 3CL protease inhibitor is called Tollovir. It is an antiviral, but it is also designed to support immune function. They also have a dietary supplement made of the same active ingredient that supports immune function.” [from a September 8, 2021 post on your social media webpage https:\u002F\u002Fwww.facebook.com\u002Ftodosmedical]\u003C\u002Fp>\n\n\u003Cp>Your website https:\u002F\u002Fwww.mytollovid.com also contains evidence of intended use in the form of personal testimonials recommending or describing the use of Tollovid for the cure, mitigation, treatment, or prevention of disease (https:\u002F\u002Fmytollovid.com\u002Fpages\u002Ftestimonials). Examples of such testimonials include:\u003C\u002Fp>\n\n\u003Cp>J. Reese on November 14, 2021\u003Cbr>\n“A 5-day dosing regimen of Tollovid, from all the research I have done on 3CL Protease inhibitors, should keep the [infection] from replicating to the point I need hospitalization. A small price to pay for my health.”\u003C\u002Fp>\n\n\u003Cp>Anonymous on September 27, 2021\u003Cbr>\n“Excited to boost my immune system and not worry anymore in unmasked situations!! Work in retail and desired extra protection against illness during uncertain times.”\u003C\u002Fp>\n\n\u003Cp>Keegan B. on January 12, 2021\u003Cbr>\n“I believe Tollovid helps … When I found out I tested positive, I immediately ordered a bottle of Tollovid. I took 6 capsules a day, and I believe it helped me in the fight against this disease. I am fortunate to have known about this product because I do believe it gave me an advantage to a quick recovery . . .”\u003C\u002Fp>\n\n\u003Cp>Michael B. on December 8, 2020\u003Cbr>\n“My family and I were directly exposed a few weeks ago, we had just started taking Tollovid and no one in my family contracted it while the other family we were with all ended up positive and sick. While there is no way of proving it was because of taking Tollovid, I’m grateful we were on it and will continue to take it.‘\"\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address this matter. This letter is not meant to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. Within 48 hours, please send an email to \u003Cstrong>COVID-19-Task-Force-CFSAN@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CFSAN@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn M. Oxenham Director\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), \u003Cem>available at\u003C\u002Fem> \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-%20concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency- concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nGerald Commissiong\n\nRecipient Title\n\nCEO\u002FDirector\n\nTodos Medical Ltd aka Todos Medical USA Inc\n\n40 Wall Street Suite 2702\n\nNew York, NY 10005\n\nUnited States\n\ngerald@todosmedical.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nDate: November 7, 2022\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fwww.todosmedical.com, https:\u002F\u002Fwww.mytollovid.com and https:\u002F\u002Fwww.tollovid.myshopify.com on June 23, 2022. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Ftodosmedical and https:\u002F\u002Fwww.youtube.com\u002Fchannel\u002FUCWsJLl1iB9qlZUSicQ9e-Mg, where you direct consumers to your websites https:\u002F\u002Fwww.mytollovid.com and https:\u002F\u002Fwww.todosmedical.com, respectively, to purchase your products. Additionally, we reviewed your product listings on your Amazon storefront at https:\u002F\u002Fwww.amazon.com\u002Fs?ie=UTF8&marketplaceID=ATVPDKIKX0DER&me=A1DTBIYVC3OVND. The FDA has observed that your websites and your Amazon storefront offer the product Tollovid 3CL Protease Inhibitor Delayed Release (Tollovid) for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your websites that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n• “3CL Protease Inhibitors: The Potential Key to Combating the SARS-CoV-2 Virus Life Cycle . . . Studies have shown … that by using protease inhibitors, we can stop the virus’ ability to replicate itself, halting the spread in it [sic] tracks.” [from your website https:\u002F\u002Ftodosmedical.com\u002F3cl- protease-inhibitors?hsLang=en]\n\n• Under the heading “Protease Inhibitors”:\n\n“Todos has acquired exclusive distribution rights to the immune boosting, dietary supplement Tollovid™ and is developing Tollovir,™ a highly potent 3CL protease inhibitor as a COVID-10 antiviral.” [from your homepage at https:\u002F\u002Fwww.todosmedical.com]\n\n• \"What is a 3CL Protease?\n\nFormally known as C3 Endopeptidase, the main protease found in coronaviruses.\" [from https:\u002F\u002Fmytollovid.com\u002Fa\u002Ffaq]\n\n• \"Todos Medical featured in a new Seeking Alpha article: Pfizer's #3CL #Protease #Inhibitor May Cut the Achilles’ Heel of #COVID19\n\n. . .\n\nTodos . . .has a promising pipeline of products . . . Its 3CL protease inhibitor is called Tollovir. It is an antiviral, but it is also designed to support immune function. They also have a dietary supplement made of the same active ingredient that supports immune function.” [from a September 8, 2021 post on your social media webpage https:\u002F\u002Fwww.facebook.com\u002Ftodosmedical]\n\nYour website https:\u002F\u002Fwww.mytollovid.com also contains evidence of intended use in the form of personal testimonials recommending or describing the use of Tollovid for the cure, mitigation, treatment, or prevention of disease (https:\u002F\u002Fmytollovid.com\u002Fpages\u002Ftestimonials). Examples of such testimonials include:\n\nJ. Reese on November 14, 2021\n\n“A 5-day dosing regimen of Tollovid, from all the research I have done on 3CL Protease inhibitors, should keep the [infection] from replicating to the point I need hospitalization. A small price to pay for my health.”\n\nAnonymous on September 27, 2021\n\n“Excited to boost my immune system and not worry anymore in unmasked situations!! Work in retail and desired extra protection against illness during uncertain times.”\n\nKeegan B. on January 12, 2021\n\n“I believe Tollovid helps … When I found out I tested positive, I immediately ordered a bottle of Tollovid. I took 6 capsules a day, and I believe it helped me in the fight against this disease. I am fortunate to have known about this product because I do believe it gave me an advantage to a quick recovery . . .”\n\nMichael B. on December 8, 2020\n\n“My family and I were directly exposed a few weeks ago, we had just started taking Tollovid and no one in my family contracted it while the other family we were with all ended up positive and sick. While there is no way of proving it was because of taking Tollovid, I’m grateful we were on it and will continue to take it.‘\"\n\nYou should take immediate action to address this matter. This letter is not meant to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CFSAN@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products.\n\nOnce you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CFSAN@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham Director\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n______________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency- concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Todos Medical Ltd aka Todos Medical USA Inc","todos-medical-ltd-aka-todos-medical-usa-inc-626258-11072022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftodos-medical-ltd-aka-todos-medical-usa-inc-626258-11072022","2026-10-26T08:10:13.369562+00:00","2023-03-28","626258","Food & Beverages","Gerald Commissiong","2026-08-20T01:10:44.782+00:00","2022-11-07",4,{"510k":98,"classification":99,"enforcement":100,"event":101,"event_backfill":102,"pma":103,"warning_letter":104},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]